The flock receives EU Conditional Marketing Authorization for our first product, ZYNTEGLO™ (autologous CD34⁺ cells encoding β^A-T87Q-globin gene)

Our nest in North Carolina is open for business!

bluebird bio announces exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Inhibrx’s proprietary single domain antibody (sdAb) platform to multiple cancer targets.

bluebird bio announces European Medicines Agency’s Acceptance of Marketing Authorization Application of our investigational treatment for patients with transfusion-dependent β-thalassemia.

bluebird bio announces a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.

bluebird bio announces collaboration with Regeneron to discover, develop and commercialize new cell therapies for cancer

bluebird's investigational gene therapy for cerebral ALD was granted Breakthrough Therapy designation by the U.S. FDA.

Each bird is allowed to invite 1-2 people that inspire them to visit the office and to see what we do here on behalf of patients. Our speaker and performer for year one was America’s Got Talent contestant, Mandy Harvey.

Collaboration with TC Biopharma announced to research and develop Gamma Delta CAR T cell product candidates for cancer immunotherapy

Our Facilities team celebrates after receiving the Certificate of Occupancy for our new nest at 60 Binney, Cambridge MA.

Our manufacturing relationship with Apceth provides us with European commercial manufacturing capabilities

bluebird  bio announces strategic research and development collaboration and licensing agreement with Medigene AG for T cell receptor (TCR) immunotherapies against four targets.

Our investigational treatment for patient with transfusion-dependent β-thalassemia was given PRIME designation by European Medicines Agency (EMA)

bluebird bio announces strategic manufacturing agreement with Lonza Houston, Inc., providing for future commercial production of our drug products

Gabriella joined the nest as our first hire in Italy. We now have EU birds in Switzerland, Italy, France, the Netherlands, and the UK too!

bluebird invites Daron, a 12 year old boy fighting cancer, to be our Chief Scientific Officer for the day! All birds fly with Daron!

First patient treated with bb2121 anti-BCMA CAR T cell therapy in Phase 1 study in patients with relapsed/refractory multiple myeloma.

The first patient treated in a clinical study of our investigational treatment for sickle cell disease was a milestone for bbb and patients.

The first patient treated in a clinical study of our investigational treatment for β-thalassemia was a milestone for bbb and patients.

As bluebird continues to grow, the team moves to their new nest at 150 Second Street in Cambridge.

The all-employee auction has become an annual bluebird tradition. Each year, employees donate and bid on items to raise money for the charity of our choosing including the Ethan Zakes Foundation, Brian’s Hope, Sickle Cell Community Consortium, Thalassemia Support Foundation and most recently in 2018 for Stupid Cancer.

bluebird expands to the West Coast by acquiring some kick-ass birds with a unique gene editing platform. We now have a nest in Seattle, WA.

bluebird's initial public offering (IPO)

bluebird collaborates with Celgene to discover, develop and commercialize novel, disease-altering gene therapies in oncology.

BioBall is a one day basketball tournament that partners with the Mass Bio-Tech community to raise money for Special Olympics Massachusetts. - BioBall is now an annual tradition for bluebird.

Genetix becomes bluebird